Market Overview

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Share:
Related AKRX
Earnings Scheduled For February 26, 2015
Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks
Meet IBD's 4 A Stocks With Rising Earnings Estimates (Investor's Business Daily)
Related SLXP
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
Valeant Pharmaceuticals Is Kicking Butt, Says Canaccord Genuity
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report (Seeking Alpha)

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.

The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 18.99%. Akorn's revenue for the same period is $227.26 million.

The trailing-twelve-month return on equity at Hi Tech Pharmacal Co (NASDAQ: HITK) is 18.38%. Hi Tech Pharmacal's operating margin for the same period is 24.58%.

The trailing-twelve-month return on equity at Salix Pharmaceuticals (NASDAQ: SLXP) is 15.84%. Salix Pharmaceuticals had $775.90 million in total cash for the latest quarter.

The trailing-twelve-month return on equity at Mylan (NASDAQ: MYL) is 14.65%. Mylan's PEG ratio is 0.72.

Posted-In: Drugs-Generic Industry highest ROE NASDAQTrading Ideas

 

Related Articles (AKRX + HITK)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→